Jim R. Gibson serves as Chief Financial Officer at Pacific Biosciences of California, Inc. (PacBio), a pioneer in long-read DNA sequencing and genomics technologies. In this pivotal role since 2021, he oversees all financial operations, including strategic planning, investor relations, treasury management, and capital allocation to support the company's innovation in scalable sequencing platforms. Gibson's leadership has been instrumental in optimizing PacBio's financial structure amid rapid technological advancements and market expansion in the life sciences sector. With more than 25 years of experience in biotechnology and pharmaceuticals, Gibson previously held the CFO position at Kura Oncology from 2018 to 2021, where he spearheaded the company's IPO and raised over $300 million through equity financings to fuel its oncology drug development pipeline. Earlier, as CFO of Synageva BioPharma, he guided the firm through its successful IPO and a landmark $8.4 billion acquisition by Alexion Pharmaceuticals in 2015. His career also includes senior finance roles at Genzyme Corporation, contributing to global expansions, product launches, and mergers. Gibson's achievements include navigating multiple high-stakes financings, acquisitions, and public offerings that have delivered substantial shareholder value. A Wharton MBA and BS in Finance from the University of Florida graduate, he brings deep expertise in scaling biotech enterprises, positioning PacBio for sustained growth and leadership in precision genomics.